| Patents for A61P 17 - Drugs for dermatological disorders (106,455) |
|---|
| 04/22/2004 | WO2004033412A1 Novel beta mimetics with extended duration of action, method for production and use thereof as medicaments |
| 04/22/2004 | WO2004032964A1 Remedies for allergic diseases |
| 04/22/2004 | WO2004032946A1 Cutaneous wrinkle treatment agent |
| 04/22/2004 | WO2004032945A1 Active ingredient combinations of polyhexamethylenebiguanidine hydrochloride and distearyldimethylammonium chloride and preparations comprising said active ingredient combinations |
| 04/22/2004 | WO2004032941A1 Pharmaceutical compositions containing polydatin or its salts and their application |
| 04/22/2004 | WO2004032914A2 Use of a propargyl alcohol enantiomer for the treatment of dermatological disorders |
| 04/22/2004 | WO2004032912A1 Medicine comprising a thiourea for use as depigmenting agent or anti-mutagenic and anti-carcinogenic agent |
| 04/22/2004 | WO2004032911A2 Styrylacrylonitrile compounds for inhibition of vascular endothelial growth factor |
| 04/22/2004 | WO2004032879A2 Compounds, compositions, and methods |
| 04/22/2004 | WO2004018431A3 Novel phenanthridines |
| 04/22/2004 | WO2004017948A3 Use of lck inhibitor for treatment of immunologic diseases |
| 04/22/2004 | WO2004010945A3 Cyclooxygenase- 2 selective inhibitors, compositions and methods of use |
| 04/22/2004 | WO2004009784A3 Novel inhibitors of kinases |
| 04/22/2004 | WO2004005310A3 New compounds, compositions and methods for treatment of inflammatory diseases and conditions |
| 04/22/2004 | WO2004005243A3 Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives |
| 04/22/2004 | WO2003087318A9 Truncated 24 kda basic fibroblast growth factor |
| 04/22/2004 | WO2003068937A3 Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells |
| 04/22/2004 | WO2003064625A3 Oligonucleotide compositions with enhanced efficiency |
| 04/22/2004 | WO2003041728A9 Novel phenyl-propargylether derivatives |
| 04/22/2004 | WO2003015809A9 Antimicrobial cationic peptides and formulations thereof |
| 04/22/2004 | WO2002074767A8 Metalloproteinase inhibitors |
| 04/22/2004 | WO2002074752A8 Metalloproteinase inhibitors |
| 04/22/2004 | WO2002074748A8 Metalloproteinase inhibitors |
| 04/22/2004 | WO2002062970A8 Enteric nervous system derived stem and progenitor cells and uses thereof |
| 04/22/2004 | US20040077896 Compounds for the treatment of metabolic disorders |
| 04/22/2004 | US20040077877 Jun n-terminal kinase inhibitors |
| 04/22/2004 | US20040077875 (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2 -thiazolyl)carbamic Acid, 1,1-dimethylethyl ester for example; treating immunological and oncological disorders such as inflammatory bowel disease or cancer |
| 04/22/2004 | US20040077728 Retiferol derivatives and their use in the treatment of skin diseases or conditions associated with photodamage |
| 04/22/2004 | US20040077726 Antiproliferative and anticarcinogenic agents; psoriasis |
| 04/22/2004 | US20040077722 Cosmetics for dermatological treatment and prevention of skin aging due to actinic radiation |
| 04/22/2004 | US20040077715 Use of an isothiocyanate, a thiocyanate or a mixture thereof as depigmenting agent |
| 04/22/2004 | US20040077704 Fused cyclopenta-, cyclohexa-, or cyclohepta(g)indole derivatives as human non-pancreatic secretory phospholipase inhibitors; antiinflammatory agents |
| 04/22/2004 | US20040077695 Anticarcinogenic, antiallergen, and antiinflammatory agents; autoimmuned diseases |
| 04/22/2004 | US20040077693 Integrin receptor inhibitors |
| 04/22/2004 | US20040077688 Treating psoriasis, gastroesophageal reflux, Zollinger-Ellison Syndrome; antiulcer and antisecretory agents |
| 04/22/2004 | US20040077684 Piperidinyl compounds that selectively bind integrins |
| 04/22/2004 | US20040077681 Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors |
| 04/22/2004 | US20040077678 Urea substituted imidazoquinoline ethers |
| 04/22/2004 | US20040077667 Quinazolinone derivatives |
| 04/22/2004 | US20040077658 Respiratory system, nervous system, brain, gastrointestinal and psychological disorders; chronic obstructive pulmonary disease; antiasthmatics, analgesics |
| 04/22/2004 | US20040077648 Antiproliferative agents for smooth muscle cells; antiinflammatory agents for endothelial cells; restenosis, atherosclerosis |
| 04/22/2004 | US20040077643 3,4 Dihydroisoquinoline derivative compounds and drugs containing these compounds as the active ingredient |
| 04/22/2004 | US20040077642 Pyrimidine compounds |
| 04/22/2004 | US20040077612 Acting as prodrugs; higher concentration delivery of active material to target cell in hybrid form; decreasing side effects |
| 04/22/2004 | US20040077552 Inflammation-inhibiting compounds |
| 04/22/2004 | US20040077523 Using matrix metalloproteinase inhibitor; preventing post-menopausal sagging |
| 04/22/2004 | US20040077079 Methods, kits and production plant for use in the production of cell colony forming units from a mammalian tissue explant and to the use of cells from such cell colony forming units in treatment of mammals suffering from tissue disorders |
| 04/22/2004 | US20040076986 A gene and/or a protein involved in the prevention or treatment of allergic diseases and dermatitis |
| 04/22/2004 | US20040076985 Reagents which regulate human chemokine-like receptor and reagents which bind to human chemokine-like receptor gene products, useful in preventing, ameliorating, or correcting dysfunctions or diseases including HIV infection, |
| 04/22/2004 | US20040076689 Obtained by extracting Astragali Radix, Ginseng Radix, Carthami Flos, Angelicae Gigantis Radix, Cnidii Rhizoma, Rehmanniae Radix Preparata, Paeoniae Radix and Cinnamomi Cortex Spissus with water while heating |
| 04/22/2004 | US20040076680 Obtained by means of physico-chemical crosslinking of the derivatives of high-molecular-weight hyaluronic acid or salts thereof; antiarthritic agents |
| 04/22/2004 | US20040076626 Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L |
| 04/22/2004 | US20040076625 A fusion proteins comprising self or non-self antigens, is used for treatment and prevention of immunoglobulin E related diseases, gene expression |
| 04/22/2004 | US20040076614 For natural cellular immune defense in humans/animals; for foods/feeds |
| 04/22/2004 | US20040076608 Cytokine uses; compositions; methods |
| 04/22/2004 | US20040076601 Pharmaceutical form comprising a cell regulating factor and/or a cell proliferation promoter |
| 04/22/2004 | US20040076597 Comprises advanced glycosylation endproducts |
| 04/22/2004 | DE10153346A1 Substituierte Indole Substituted indoles |
| 04/22/2004 | CA2501742A1 Medicine comprising a thiourea for use as depigmenting agent or anti-mutagenic and anti-carcinogenic agent |
| 04/22/2004 | CA2501055A1 Novel betamimetics with extended duration of action, method for production and use thereof as medicaments |
| 04/22/2004 | CA2500385A1 Styrylacrylonitrile compounds for inhibition of vascular endothelial growth factor |
| 04/21/2004 | EP1411354A1 Method of detecting skin stimulation effect |
| 04/21/2004 | EP1411128A1 Recombinant viral and non-viral vectors containing the human urokinase plasminogen activator gene and its utilization in the treatment of various types of hepatic, renal, pulmonary, pancreatic and cardiac fibrosis and hypertrophic scars |
| 04/21/2004 | EP1410822A1 Oxa(thia)zolidine compounds, process for preparation thereof and anti-inflammatory agents |
| 04/21/2004 | EP1410796A2 New therapeutic uses for potassium channel openers |
| 04/21/2004 | EP1410038A2 Assays for identifying modulators of rhomboid polypeptides |
| 04/21/2004 | EP1410018A1 Method for detecting modultators of notch signalling |
| 04/21/2004 | EP1409737A2 Methods for detecting and treating the early onset of aging-related conditions |
| 04/21/2004 | EP1409677A2 Receptors and membrane-associated proteins |
| 04/21/2004 | EP1409672A2 Antisense oligonucleotides which can inhibit the formation of capillary tubes by endothelial cells |
| 04/21/2004 | EP1409668A2 Antisense nucleic acid against alphav integrin |
| 04/21/2004 | EP1409655A2 Immunoglobulin superfamily proteins |
| 04/21/2004 | EP1409645A1 Probiotic lactobacillus salivarius strains |
| 04/21/2004 | EP1409644A1 Probiotic bifidobacterium strains |
| 04/21/2004 | EP1409539A1 Method for obtaining a tgf-beta enriched protein fraction in activated form, protein fraction and therapeutic applications |
| 04/21/2004 | EP1409535A2 Human secreted proteins |
| 04/21/2004 | EP1409525A2 Human papillomavirus e2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket |
| 04/21/2004 | EP1409513A1 Methylene-4-azasteroids |
| 04/21/2004 | EP1409494A1 Stabilized derivatives of ascorbic acid -3- phosphate |
| 04/21/2004 | EP1409489A1 6-phenyldihydropyrrolopyrimidinedione derivatives |
| 04/21/2004 | EP1409487A1 Pteridinones as kinase inhibitors |
| 04/21/2004 | EP1409485A1 Novel immunomodulating compounds |
| 04/21/2004 | EP1409481A1 Quinoline derivatives and their use as tyrosine kinase inhibitors |
| 04/21/2004 | EP1409467A1 Synthesis of udp-glucose: n-acylsphingosine glucosyltransferase inhibitors |
| 04/21/2004 | EP1409463A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 04/21/2004 | EP1409034A1 Topical pharmaceutical formulation |
| 04/21/2004 | EP1409022A1 Pharmaceutical vehicle |
| 04/21/2004 | EP1409015A1 Methods for treating or preventing skin disorders using cd2-binding agents |
| 04/21/2004 | EP1409008A1 Use of the disintegrin domain of an adamalysin as anti-angiogenic, anti-invasive and anti-metastatic agent |
| 04/21/2004 | EP1409007A2 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof |
| 04/21/2004 | EP1409005A1 Modulators of notch signalling for use in immunotherapy |
| 04/21/2004 | EP1409000A4 Use of agaricus blazei murill to prevent or treat skin and other disorders |
| 04/21/2004 | EP1409000A1 Use of agaricus blazei murill to prevent or treat skin and other disorders |
| 04/21/2004 | EP1408987A2 Tetracycline compounds having target therapeutic activities |
| 04/21/2004 | EP1408966A1 A synergistic pharmaceutical combination for the prevention or treatment of diabetes |
| 04/21/2004 | EP1408947A2 Fumaric acid derivatives as nf-kappab inhibitors |
| 04/21/2004 | EP1408943A2 Pharmaceutical formulation containing an ltb4 antagonist |
| 04/21/2004 | EP1408931A1 Modifying the fatty acid composition of cell membranes of organs and tissues |
| 04/21/2004 | EP1408924A1 Stabilized ascorbic acid, composition, and method of use |
| 04/21/2004 | EP1408913A2 Methods for promotion of hair growth comprising topical application of prostaglandin analogues |